Kallikrein 11 anticorps (C-Term)

N° du produit ABIN2466873

Détail du produit anti-Kallikrein 11 anticorps

Antigène: Kallikrein 11 (KLK11)

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Kallikrein 11 est non-conjugé

Application: Western Blotting (WB)

Purification: Immunoaffinity chroma-tography

Immunogène: Synthetic peptide corresponding to aa residues 68-82 of human Hippostatin conjugated to KLH at the C-terminus.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Stock: 4 °C

Stockage commentaire: KLK11 antibody can be stored at 4 °C, stable for one year.

Détails sur Kallikrein 11

Antigène: Kallikrein 11 (KLK11)

Autre désignation: KLK11 (KLK11 Produits)

Synonymes: anticorps KLK11, anticorps 2310015I08Rik, anticorps Prss20, anticorps TLSP, anticorps PRSS20, anticorps kallikrein related peptidase 11, anticorps kallikrein related-peptidase 11, anticorps kallikrein-related peptidase 11, anticorps KLK11, anticorps Klk11

Sujet: Hippostatin, also known as KLK11, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type. Hippostatin plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of KLK11 were found in 70 % of women with ovarian cancer and in 60 % of men with prostate cancer. Analysis of the KLK11 biomarker in serum may aid in the diagnosis and monitoring of ovarian and prostatic carcinoma.

ID gène: 9134

UniProt: O96020

Pathways: Système du Complément